Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection

Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives

“…In addition, no deaths were reported in the paxlovid group as compared to 10 deaths (1.6%) in the placebo group ( 157 ). During the pandemic of COVID-19 in Shanghai (2022), scientists found that unvaccinated, delayed use of paxlovid (started 5 days after diagnosis) and immunosuppressive status were independent risk factors for delayed virus clearance ( 158 ). Compared with patients who delayed paxlovid treatment, immunosuppressive patients who began to use paxlovid within 5 days after diagnosis had an earlier virus clearance time of about 6 days.…”

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

“…31 Since it usually takes a few days for cases to be identified after symptom onset, it is essential that the delay between case detection and treatment is as short as possible. 32 This requires the development of a comprehensive system that integrates both testing and treatment, ensuring rapid detection of symptomatic cases, fast turnaround of test results and delivery of treatment. An important challenge is that contraindications for nirmatrelvir/ritonavir, mainly related to drug-drug interactions, are common so that, in France, a medical consultation is required before treatment can be delivered.…”

“…(136-181) hospital admissions are expected within three months (Figure 3A), while respectively 26 (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34), 50 and 64 (51-80) beds are required at the peak (Figure 3B). The territory has about 30 hospital beds and there is therefore a risk of saturation in the absence of pharmaceutical measures, even in an optimistic scenario for NPIs.…”

The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination

“…Have been identified and/or generated to block essential viral function that are distinct from SARS-CoV-2 receptor-binding domain targeting antibodies. These chemicals currently include: remdesivir infusions for hospitalised individuals ( Beckerman et al, 2022 ) and oral molnupiravir ( Jayk Bernal et al, 2022 , Khoo et al, 2022 *), ( Wen et al, 2022 ) and ritonavir-enhanced nirmatrelvir ( Wen et al, 2022 , Sun et al, 2022 ) that are used for COVID-19 prophylaxis or for a rapid, post-infection application ( Sun et al, 2022 ). Remdesivir prodrug is metabolised by the cytochrome P450 CYP3A4 variant leading to increased bioavailability of other CYP3A4 substrates that include some MS-related drugs ( Deb and Reeves, 2021 , Hirai et al, 2022 ).…”